Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days

We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophospham...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2021-01, Vol.56 (1), p.50-59
Main Authors: Burt, Richard K., Han, Xiaoqiang, Quigley, Kathleen, Arnautovic, Indira, Shah, Sanjiv J., Lee, Daniel C., Freed, Benjamin H., Jovanovic, Borko, Helenowski, Irene B.
Format: Article
Language:English
Subjects:
13
13/100
692/308/2779/109/1940
692/699/249/1313
Autoimmune diseases
Blood transfusion
Cardiovascular diseases
Care and treatment
Cell Biology
Complications and side effects
Cyclophosphamide
Dosage and administration
Erythrocytes
Fludarabine
Hematology
Hematopoietic stem cells
Immunoglobulins
Infections
Internal Medicine
Intravenous administration
Medicine
Medicine & Public Health
Monoclonal antibodies
Neutropenia
Phenotypes
Prevention
Public Health
Respiratory tract
Respiratory tract diseases
Risk
Risk factors
Rituximab
Safety
Scleroderma
Scleroderma (Disease)
Stem cell transplantation
Stem Cells
Systemic scleroderma
Systemic sclerosis
Testing
Transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophosphamide (60 mg/kg), while two regimens also included rituximab with or without IVIG. Treatment related mortality (TRM) was 2.4%. The mean number of days of neutropenia (ANC 
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0978-2